What it is
Semax is a synthetic peptide analogue of a fragment of adrenocorticotropic hormone, developed and registered in Russia for certain indications. It is not registered in South Africa or most other markets.
The Range
XA5 · Pen · Neuroscience research
Semax 5 mg pen
Status varies — confirm locallyEvidence: Insufficient
A synthetic ACTH-fragment analogue studied in neuroscience research. Registered as a medicine in a small number of countries only; not registered in South Africa.
Evidence highlights
Mechanism being studied
Research describes possible effects on BDNF expression and monoaminergic signalling in animal models.
Human evidence
Most clinical literature originates from a small number of research groups and is not widely replicated to contemporary international trial standards. Evidence should be considered insufficient for general conclusions.
Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.